CD52 and graft versus host disease: ALLO-715 contains a disrupted TCR alpha constant gene to reduce the risk of graft-versus-host disease (GvHD) and a disrupted CD52 gene to permit the use of ALLO-647, an anti-CD52 mAb, for selective and prolonged host lymphodepletion.